20/20 Biolabs

Intangible assets: moderate. The company lists a portfolio of patents and applications on algorithms combining tumor markers and machine learning with expiries into the 2030s to early 2040s, plus know‑how around serial velocity algorithms. However, defensibility against alternate biomarker panels or improved ctDNA/multi‑omics tests is uncertain.

Score: 55/100. Switching costs: low. Customers are municipalities, employer programs, and wellness channels; contracts appear short‑term and grant‑driven with modest integration, so switching to substitute vendors is feasible. Score: 25/100. Network effects: limited but possible.

Real‑world datasets from tens of thousands of firefighter tests and East Asian cohorts could marginally strengthen algorithms over time, yet true two‑sided network effects are weak. Score: 35/100. Cost advantage: potentially meaningful.

Protein‑biomarker tests are cheaper and easier to repeat than ctDNA; management highlights affordability and capillary collection enabling serial testing. Still, cost advantage must be balanced against clinical utility proof.

Score: 60/100. Efficient scale: low; the market can support many labs and platforms, and AIDX lacks unique infrastructure barriers. Score: 20/100. Weighted overall moat reflects higher weight on cost advantage and data compounding but discounts durability until payer‑validated outcomes are achieved.